Repligen (RGEN) Stock Price, News & Analysis

Company Overview

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $110.77 to $115.73
• 50-Day Range: $112.10 to $134.00
• 52-Week Range: $102.96 to $182.52
• Volume: 1.15 million shs
• Average Volume: 1.02 million shs
• Market Capitalization: $6.30 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $169.45
• Consensus Rating: Moderate Buy

Repligen Stock Analysis - MarketRank™

Repligen scored higher than 96% of companies evaluated by MarketBeat, and ranked 110th out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Repligen has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Repligen has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 37.21%

Earnings Growth

Earnings for Repligen are expected to grow by 37.21% in the coming year, from $1.72 to $2.36 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Repligen is -448.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Repligen is -448.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Repligen has a PEG Ratio of 2.13. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Repligen has a P/B Ratio of 3.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.40% of the float of Repligen has been sold short.

Short Interest Ratio / Days to Cover

Repligen has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in Repligen has recently decreased by 9.81%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Repligen does not currently pay a dividend.

Dividend Growth

Repligen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -1.33

Percentage of Shares Shorted

6.40% of the float of Repligen has been sold short.

Short Interest Ratio / Days to Cover

Repligen has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in Repligen has recently decreased by 9.81%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.62

News Sentiment

Repligen has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 27 news articles for Repligen this week, compared to 9 articles on an average week.

Search Interest

Only 2 people have searched for RGEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Repligen insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.20% of the stock of Repligen is held by insiders.

Percentage Held by Institutions

97.64% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RGEN Stock Analysis - Frequently Asked Questions

How have RGEN shares performed this year?

Repligen's stock was trading at $143.94 on January 1st, 2025. Since then, RGEN shares have decreased by 22.1% and is now trading at $112.10.

How were Repligen's earnings last quarter?

Repligen Corporation (NASDAQ:RGEN) announced its quarterly earnings data on Tuesday, July, 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.40 by $0.03. The business's revenue was up 14.8% compared to the same quarter last year.
Read the conference call transcript.

Does Repligen have any subsidiaries?

Repligen subsidiaries include these companies: ARTeSYN Biosolutions Holdings Ireland Limite, Non-Metallic Solutions Inc, Engineered Molding Technology LLC, C Technologies Inc., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, and others.

Who are Repligen's major shareholders?

Repligen's top institutional investors include Conestoga Capital Advisors LLC (1.74%), Stephens Investment Management Group LLC (0.93%), Geneva Capital Management LLC (0.87%) and Riverbridge Partners LLC (0.66%). Insiders that own company stock include Anthony Hunt, Karen A Dawes, Jon Snodgres, Christine Gebski, Ralf Kuriyel, James Bylund, Martin D Madaus and Margaret Pax.
View institutional ownership trends.

How do I buy shares of Repligen?

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Repligen investors own include NVIDIA (NVDA), Humana (HUM), Meta Platforms (META), Salesforce (CRM), CrowdStrike (CRWD), Broadcom (AVGO) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 7/29/2025
• Today: 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RGEN
• CIK: 730272
• Web: www.repligen.com
• Phone: (781) 250-0111
• Fax: 781-250-0115
• Employees: 1,778
• Year Founded: 1981

Price Target and Rating

• Average Price Target for Repligen: $169.45
• High Price Target: $204.00
• Low Price Target: $130.00
• Potential Upside/Downside: +51.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 65.17
• P/E Growth: 2.13
• Net Income: -$25.51 million
• Net Margins: -2.05%
• Pretax Margin: -2.02%
• Return on Equity: 4.65%
• Return on Assets: 3.26%

Debt

• Debt-to-Equity Ratio: 0.27
• Current Ratio: 6.79
• Quick Ratio: 5.79

Sales & Book Value

• Annual Sales: $634.44 million
• Price / Sales: 9.93
• Cash Flow: $3.01 per share
• Price / Cash Flow: 37.30
• Book Value: $35.21 per share
• Price / Book: 3.18

Miscellaneous

• Outstanding Shares: 56,180,000
• Free Float: 55,509,000
• Market Cap: $6.30 billion
• Optionable: Optionable
• Beta: 1.05